Skip to Content
Merck
All Photos(1)

Key Documents

1604665

USP

Risperidone System Suitability Mixture

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

risperidone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

General description

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.

Application

Risperidone System Suitability Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG
The New England Journal of Medicine, 346(1), 16-22 (2002)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G
Journal of Clinical Psychopharmacology, 13(1), 25-40 (1993)
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Kapur S
Life Sciences, 57(10), PL103-PL107 (1995)
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H
The Journal of Clinical Psychiatry, 64(2), 134-143 (2003)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service